THE PROJECT ALS MISSION
Project ALS identifies and funds the most promising scientific research that will lead to the first effective treatments and a cure for ALS. We recruit the world’s best scientists and doctors to work together—rationally and aggressively—to develop a better understanding of the ALS disease process and, in parallel, better therapeutic strategies.
Read about the latest updates in ALS research, and see the Project ALS research philosophy – something we’re proud to say has accelerated the pace of research.
WHAT'S NEW WITH PROJECT ALS
New Model and Gene Targeting Approach Show Promise for ALS Therapies
Researchers from the Project ALS Therapeutics Core at Columbia (the Core), in a groundbreaking collaborative effort with Ionis Pharmaceuticals, have developed a new tool for studying ALS mechanisms and therapies, as well as a novel approach for treating ALS caused by mutations…
Announcing the Project ALS Research Advisory Board
Project ALS Announces Research Advisory Board 2.0 Non-Profit ALS Research Leader Gathers a Diversity of Expertise to Guide Next-Phase Progress (New York, NY) Project ALS, a non-profit 501(c)3 leader in the pursuit of treatments and a cure for the neurodegenerative disease ALS, has announced its research advisory board (RAB). The newly minted RAB represents a range of experience and expertise across the fields of neuroscience, clinical research,
Amylyx, the Core, and the Power of Collaboration
On Wednesday, Amylyx Pharmaceuticals announced that they are planning to file a New Drug Application—the formal submission for a drug to be approved by the FDA—for their investigational drug, AMX0035, for the treatment of ALS by the end of the year. This announcement reverses previous statements in which the company stated that the FDA would require a full Phase 3 clinical trial before Amylyx could submit for approval. First and